Long term oncostatin M treatment induces an osteocyte-like differentiation on osteosarcoma and calvaria cells

被引:15
作者
Brounais, Benedicte [2 ]
David, Emmanuelle [2 ]
Chipoy, Celine [2 ]
Trichet, Valerie [2 ]
Ferre, Virginie [3 ,4 ]
Charrier, Celine [2 ]
Duplomb, Laurence [2 ,3 ]
Berreur, Martine [2 ]
Redini, Francoise [2 ]
Heymann, Dominique [2 ,3 ]
Blanchard, Frederic [1 ,2 ]
机构
[1] Univ Nantes, Fac Med, Nantes Atlantique Univ,EA3822, Lab Physiopathol Resorpt Osseuse & Therapie Tumeu, F-44035 Nantes 1, France
[2] INSERM, ERI 7, F-44035 Nantes, France
[3] CHU Nantes, Hotel Dieu, F-44035 Nantes 01, France
[4] Univ Nantes, Nantes Atlantique Univ, Lab Immunovirol & Polymorphisme Genet, EA271, F-44035 Nantes 1, France
关键词
Oncostatin M; Lentivirus; Osteosarcoma; Osteoblast; Osteocyte; LEUKEMIA INHIBITORY FACTOR; SIGNAL TRANSDUCER; IN-VITRO; EXPRESSION; GROWTH; INTERLEUKIN-6; PROTEIN; BONE; ACTIVATION; CYTOKINES;
D O I
10.1016/j.bone.2008.12.021
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Previous in vitro studies on primary osteoblastic and osteosarcoma cells (normal and transformed osteoblasts) have shown that oncostatin M (OSM), a member of the interleukin-6 family, possesses cytostatic and pro-apoptotic effects in association with complex and poorly understood activities on osteoblast differentiation. In this study, we use rat osteosarcoma cells transduced with lentiviral particles encoding OSM (IvOSM) to stably produce this cytokine. We show that after several weeks Of Culture, transduced OSRGA and ROS 17/2.8 cells are growth inhibited and sensitized to apoptosis induced by the kinase inhibitor Staurosporine (Sts). Moreover, this long term OSM treatment induces (i) a decrease in osteoblastic markets, (ii) morphological changes leading to an elongated and/or stellate shape and (iii) an increase in osteocytic markets (sclerostin and/or Ell), suggesting an osteocyte-like differentiation. We also show that non transformed rat calvaria cells transduced with IvOSM differentiate into stellate shaped cells expressing sclerostin, Ell, Phex and functional hemichannels. Together, these results indicate that osteosarcoma cells stably producing OSM do not develop resistance to this cytokine and thus could be a valuable new tool to Study the anti-cancer effect of OSM in vivo. Moreover, OSM-over-expressing osteoblastic cells differentiate into osteocyte-like cells, the major cellular contingent in bone, providing new culture conditions for this cell type which is difficult to obtain in vitro. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:830 / 839
页数:10
相关论文
共 37 条
[1]   Signaling of type II oncostatin M receptor [J].
Auguste, P ;
Guillet, C ;
Fourcin, M ;
Olivier, C ;
Veziers, J ;
PouplardBarthelaix, A ;
Gascan, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (25) :15760-15764
[2]   Endotoxin-induced renal inflammatory response - Oncostatin M as a major mediator of suppressed renin expression [J].
Baumann, H ;
Wang, YP ;
Richards, CD ;
Jones, CA ;
Black, TA ;
Gross, KW .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (29) :22014-22019
[3]   Transcriptional activation of the p21WAF1,CIP1,SDI1 gene by interleukin-6 type cytokines -: A prerequisite for their pro-differentiating and anti-apoptotic effects on human osteoblastic cells [J].
Bellido, T ;
O'Brien, CA ;
Roberson, PK ;
Manolagas, SC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (33) :21137-21144
[4]   Activation of the Janus kinase/STAT (signal transducer and activator of transcription) signal transduction pathway by interleukin-6-type cytokines promotes osteoblast differentiation [J].
Bellido, T ;
Borba, VZC ;
Roberson, P ;
Manolagas, SC .
ENDOCRINOLOGY, 1997, 138 (09) :3666-3676
[5]   Osteocytes, mechanosensing and Wnt signaling [J].
Bonewald, Lynda F. ;
Johnson, Mark L. .
BONE, 2008, 42 (04) :606-615
[6]   Oncostatin M induces bone loss and sensitizes rat osteosarcoma to the antitumor effect of midostaurin in vivo [J].
Brounais, Benedicte ;
Chipoy, Celine ;
Mori, Kanji ;
Charrier, Celine ;
Battaglia, Severine ;
Pilet, Paul ;
Richards, Carl D. ;
Heymann, Dominique ;
Redini, Francoise ;
Blanchard, Frederic .
CLINICAL CANCER RESEARCH, 2008, 14 (17) :5400-5409
[7]   Oncostatin M: a pleiotropic cytokine in the central nervous system [J].
Chen, SH ;
Benveniste, EN .
CYTOKINE & GROWTH FACTOR REVIEWS, 2004, 15 (05) :379-391
[8]   Sensitization of osteosarcoma cells to apoptosis by oncostatin M depends on STAT5 and p53 [J].
Chipoy, C. ;
Brounais, B. ;
Trichet, V. ;
Battaglia, S. ;
Berreur, M. ;
Oliver, L. ;
Juin, P. ;
Redini, F. ;
Heymann, D. ;
Blanchard, F. .
ONCOGENE, 2007, 26 (46) :6653-6664
[9]   Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin m in osteosarcoma cells require PKCδ and STAT3 [J].
Chipoy, C ;
Berreur, M ;
Couillaud, S ;
Pradal, G ;
Vallette, F ;
Colombeix, C ;
Rédini, F ;
Heymann, D ;
Blanchard, F .
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (11) :1850-1861
[10]   Adenoviral transfer of murine oncostatin M elicits periosteal bone apposition in knee joints of mice, despite synovial inflammation and up-regulated expression of interleukin-6 and receptor activator of nuclear factor-κB ligand [J].
de Hooge, ASK ;
van de Loo, FAJ ;
Bennink, MB ;
de Jong, DS ;
Arntz, OJ ;
Lubberts, E ;
Richards, CD ;
van den Berg, WB .
AMERICAN JOURNAL OF PATHOLOGY, 2002, 160 (05) :1733-1743